tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2015 Apr 2:0. [Epub ahead of print]
[h=1]Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.[/h] Jacobson RM[SUP]1[/SUP], Grill DE, Oberg AL, Tosh PK, Ovsyannikova IG, Poland GA.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] To identify distinct antibody profiles among adults 50-to-74 years old using influenza A/H1N1 HI titers up to 75 days after vaccination.
[h=4]METHODS:[/h] Healthy subjects 50 to 74 years old received the 2010-2011 trivalent inactivated influenza vaccine. We measured venous samples from Days 0, 28, and 75 for HI and VNA and B-cell ELISPOTs.
[h=4]RESULTS:[/h] Of 106 subjects, HI titers demonstrated a ceiling effect for 11 or 10% for those with a pre-vaccination HI titer of 1:640 where no subject post-vaccination had an increase in titer. Of the remaining 95 subjects, only 37 or 35% overall had at least a four-fold increase by Day 28. Of these 37, three waned at least four-fold, and 13 others two-fold. Thus 15% of the subjects showed waning antibody titers by Day 75. More than half failed to respond at all. The profiles populated by these subjects as defined by HI did not vary with age or gender. The VNA results mimicked the HI profiles, but the profiles for B-cell ELISPOT did not.
[h=4]DISCUSSION:[/h] HI titers at Days 0, 28, and 75 populate four biologically plausible profiles. Limitations include lack of consensus for operationally defining waning as well as for the apparent ceiling. Furthermore, though well accepted as a marker for vaccine response, assigning thresholds with HI has limitations. However, VNA closely matches HI in populating these profiles. Thus, we hold that these profiles, having face- and content-validity, may provide a basis for understanding variation in genomic and transcriptomic response to influenza vaccination in this age group.
[h=4]KEYWORDS:[/h] ASC Antibody-Secreting Cells; Aging; Antibodies; ELISPOT Enzyme-Linked ImmunoSpot; Et al. Et alia (and others); H1N1 Subtype; HI Hemagglutination-Inhibition; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins; IQR Interquartile Range; IgG Immunoglobulin G; Influenza A Virus; Influenza Vaccines; Influenza Virus; MDCK Madin-Darby Canine Kidney; PFU Plaque-Forming Units; RBC Red Blood Cells; TCID50 Tissue Culture Infectious Dose 50; VNA Virus Neutralization Assay; Viral; WHO World Health Organization; p p-value; μl Microliters
PMID: 25835513 [PubMed - as supplied by publisher]
[h=1]Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.[/h] Jacobson RM[SUP]1[/SUP], Grill DE, Oberg AL, Tosh PK, Ovsyannikova IG, Poland GA.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] To identify distinct antibody profiles among adults 50-to-74 years old using influenza A/H1N1 HI titers up to 75 days after vaccination.
[h=4]METHODS:[/h] Healthy subjects 50 to 74 years old received the 2010-2011 trivalent inactivated influenza vaccine. We measured venous samples from Days 0, 28, and 75 for HI and VNA and B-cell ELISPOTs.
[h=4]RESULTS:[/h] Of 106 subjects, HI titers demonstrated a ceiling effect for 11 or 10% for those with a pre-vaccination HI titer of 1:640 where no subject post-vaccination had an increase in titer. Of the remaining 95 subjects, only 37 or 35% overall had at least a four-fold increase by Day 28. Of these 37, three waned at least four-fold, and 13 others two-fold. Thus 15% of the subjects showed waning antibody titers by Day 75. More than half failed to respond at all. The profiles populated by these subjects as defined by HI did not vary with age or gender. The VNA results mimicked the HI profiles, but the profiles for B-cell ELISPOT did not.
[h=4]DISCUSSION:[/h] HI titers at Days 0, 28, and 75 populate four biologically plausible profiles. Limitations include lack of consensus for operationally defining waning as well as for the apparent ceiling. Furthermore, though well accepted as a marker for vaccine response, assigning thresholds with HI has limitations. However, VNA closely matches HI in populating these profiles. Thus, we hold that these profiles, having face- and content-validity, may provide a basis for understanding variation in genomic and transcriptomic response to influenza vaccination in this age group.
[h=4]KEYWORDS:[/h] ASC Antibody-Secreting Cells; Aging; Antibodies; ELISPOT Enzyme-Linked ImmunoSpot; Et al. Et alia (and others); H1N1 Subtype; HI Hemagglutination-Inhibition; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins; IQR Interquartile Range; IgG Immunoglobulin G; Influenza A Virus; Influenza Vaccines; Influenza Virus; MDCK Madin-Darby Canine Kidney; PFU Plaque-Forming Units; RBC Red Blood Cells; TCID50 Tissue Culture Infectious Dose 50; VNA Virus Neutralization Assay; Viral; WHO World Health Organization; p p-value; μl Microliters
PMID: 25835513 [PubMed - as supplied by publisher]